BBDF: CORRECTION FROM SOURCE: Theranexus and BBDF Win FDA Approval on Efficacy Endpoints for the Phase III Trial to Evaluate Batten-1 in CLN3 Batten Disease

This press release updates an earlier issuance with updated language throughout.Phase III's primary endpoint will be visual acuity, with secondary endpoints including assessment of cognitive and mo...